This CE symposium will provide clinicians with an overview of the novel treatment strategies for patients with Alzheimer’s disease (AD). Three expert faculty will review recent advances in prevention techniques, diagnostic criteria and clinical assessment for patients with AD. An analysis of clinical trial data for emerging therapeutics to improve outcomes in patients with Alzheimer’s disease will be discussed. The faculty will also review how to apply a precision medicine approach with the interprofessional team to develop effective treatment plans for patients with AD. Upon competition of this educational activity, healthcare providers will gain a better understanding of how to optimally assess and treat their patients with Alzheimer’s disease.
Geriatricians, neurologists, internists, primary care physicians, physician assistants, nurse practitioners, nurses, and other healthcare professionals involved in the management of patients with Alzheimer’s diseases
- Discuss the recent advances in diagnostic criteria, genomic analysis, and clinical assessment of patients with AD.
- Analyze clinical trial data for emerging therapeutics to improve outcomes in patients with AD.
- Apply a precision medicine approach with the interprofessional team to develop effective treatment plans for patients with AD
Alireza Atri, MD, PhD
Director, Banner Sun Health Research Institute
Sun City, AZ
Lecturer on Neurology
Center for Brain/Mind Medicine
Department of Neurology
Brigham and Women’s Hospital and Harvard Medical School
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
Alireza Atri, MD, PhD
|Consultant/Advisor: Alzheimer’s Association; Allergan; Axovant Sciences Ltd.; Biogen; Eisai Co., Ltd.; F. Hoffman-La Roche Ltd.; Grifols, S.A; Harvard Medical School Graduate Continuing Education (HMS CE); Lundbeck; Merck & Co., Inc.; National Institutes of Health (NIH); Genentech, Inc.; Sunovion Pharmaceuticals, Inc.; Suven Life Science Ltd.; Synexus Clinical Research LimitedGrant/Research Support: American College of Radiology, AbbVie Inc.; Avid Technology, Inc.; Biogen, Eli Lilly and Company; Lundbeck; vTV Therapeutics|
Richard Isaacson, MD
|Grant/Research Support: NIH P01 AG026572; National Institutes of Health Clinical Research LRP; Women’s Alzheimer’s Movement; Hilarity for Charity; Weill Cornell Clinical & Translational Science Center UL1TR002384\|
Lynn W. Shaughnessy, PsyD, ABPP-CN
|Nothing to disclose|
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole Brestowski; Chelsey Benedek and Devon Dietzel hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement
AcademicCME designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™.
AcademicCME designates this enduring material for a maximum of 1.25 CNE contact hours (1.25 CNE pharmacotherapeutic contact hours). AcademicCME’s ANCC provider number is P0491.
Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Biogen.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Biogen do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions.
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
8. 60 minutes of participation = 1 CNE contact hour
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].